Research ExplorerPublicationsDevelopment of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 f...

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.

Standard

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. / Schafhausen, Philippe; Dierlamm, Judith; Bokemeyer, Carsten; Brümmendorf, Tim; Bacher, Ulrike; Zander, Axel R.; Schnittger, Susanne; Hochhaus, Andreas.

In: CANCER GENET-NY, Vol. 189, No. 1, 1, 2009, p. 63-67.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schafhausen, P, Dierlamm, J, Bokemeyer, C, Brümmendorf, T, Bacher, U, Zander, AR, Schnittger, S & Hochhaus, A 2009, 'Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.', CANCER GENET-NY, vol. 189, no. 1, 1, pp. 63-67. <http://www.ncbi.nlm.nih.gov/pubmed/19167615?dopt=Citation>

APA

Schafhausen, P., Dierlamm, J., Bokemeyer, C., Brümmendorf, T., Bacher, U., Zander, A. R., Schnittger, S., & Hochhaus, A. (2009). Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. CANCER GENET-NY, 189(1), 63-67. [1]. http://www.ncbi.nlm.nih.gov/pubmed/19167615?dopt=Citation

Vancouver

Schafhausen P, Dierlamm J, Bokemeyer C, Brümmendorf T, Bacher U, Zander AR et al. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. CANCER GENET-NY. 2009;189(1):63-67. 1.

Bibtex

@article{59b5fbd2f3c440748b6785b19a682bd6,
title = "Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.",
author = "Philippe Schafhausen and Judith Dierlamm and Carsten Bokemeyer and Tim Br{\"u}mmendorf and Ulrike Bacher and Zander, {Axel R.} and Susanne Schnittger and Andreas Hochhaus",
year = "2009",
language = "Deutsch",
volume = "189",
pages = "63--67",
journal = "CANCER GENET-NY",
issn = "2210-7762",
publisher = "Elsevier BV",
number = "1",

}

RIS

TY - JOUR

T1 - Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.

AU - Schafhausen, Philippe

AU - Dierlamm, Judith

AU - Bokemeyer, Carsten

AU - Brümmendorf, Tim

AU - Bacher, Ulrike

AU - Zander, Axel R.

AU - Schnittger, Susanne

AU - Hochhaus, Andreas

PY - 2009

Y1 - 2009

M3 - SCORING: Zeitschriftenaufsatz

VL - 189

SP - 63

EP - 67

JO - CANCER GENET-NY

JF - CANCER GENET-NY

SN - 2210-7762

IS - 1

M1 - 1

ER -